Organic Synthesis Pharmaceuticals Co., Ltd. revised its FY2027 full-year earnings forecast, expecting sales of 16,000 million yen and operating profit of 550 million yen. The outlook has been revised considering raw material procurement trends and geopolitical risks.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4531","jir_company_name":"Organic Synthesis Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4531-20260731-01.pdf","jir_short_summary":"Organic Synthesis Pharmaceuticals Co., Ltd. revised its FY2027 full-year earnings forecast, expecting sales of 16,000 million yen and operating profit of 550 million yen. The outlook has been revised considering raw material procurement trends and geopolitical risks.","jir_summary":"### Overview of Performance\nOrganic Synthesis Pharmaceuticals Co., Ltd. has revised its full-year earnings forecast for FY2027, projecting sales of 16,000 million yen, operating profit of 550 million yen, ordinary income of 500 million yen, and net income attributable to owners of parent of 600 million yen. The outlook has been adjusted considering procurement trends of raw materials and geopolitical influences in the Middle East. This reflects a policy to promote flexible management strategies to respond to future business environment fluctuations.\n\n### Future Outlook and Impact on Investors\nThere is a possibility that geopolitical risks and rising raw material and fuel prices may affect performance, and forecasts may be revised as necessary. The specific figures for the medium-term management plan will be announced once finalized. Investors should pay attention to future risk factors and the trend of profit improvements.","jir_financial_highlights":"Sales: 16,000 million yen (unknown change rate)\nOperating Income: 550 million yen (new forecast)\nOrdinary Income: 500 million yen (new forecast)\nNet Income Attributable to Owners of Parent: 600 million yen (new forecast)","jir_category":"","jir_hashtags":"#OrganicSynthesisPharmaceuticals, #IRRelated, #JapanStocks","jir_key_figures":"Sales: 16,000 million yen\nOperating Income: 550 million yen\nOrdinary Income: 500 million yen","jir_meta_title":"\u3010Organic Synthesis Pharmaceuticals\u3011 FY2027 Full-Year Earnings Forecast Revision | Sales of 16,000 million yen","jir_meta_description":"Organic Synthesis Pharmaceuticals revised its FY2027 earnings forecast, expecting sales of 16,000 million yen and improved profit outlook. Attention is required for geopolitical risks and raw material trends.","jir_og_title":"\u3010Organic Synthesis Pharmaceuticals\u3011 FY2027 Full-Year Earnings Forecast Revision","jir_og_description":"Organic Synthesis Pharmaceuticals revised its FY2027 sales to 16,000 million yen. Focus is on future risks and outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59377,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-91760","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n